Wisteria floribunda agglutinin‐positive Mac‐2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct‐acting antivirals for hepatitis C virus. Issue 13 (23rd August 2018)

• Record Type: Journal Article
• Authors: Yasui, Yutaka; Kurosaki, Masayuki; Komiyama, Yasuyuki; Takada, Hitomi; Tamaki, Nobuharu; Watakabe, Keiya; Okada, Mao; Wang, Wan; Shimizu, Takao; Kubota, Yohei; Higuchi, Mayu; Takaura, Kenta; Tsuchiya, Kaoru; Nakanishi, Hiroyuki; Takahashi, Yuka; Itakura, Jun; Enomoto, Nobuyuki; Izumi, Namiki
• Is Part Of: Hepatology research. Volume 48:Issue 13(2018)
• Page Start: 1131
• Page End: 1139
• Publication Date: 2018-08-23
• Subjects: alpha‐fetoprotein -- chronic hepatitis C -- hepatocellular carcinoma -- Wisteria floribunda agglutinin‐positive Mac‐2 binding protein; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.13233
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: The aim of this study is to clarify the value of serum Wisteria floribunda agglutinin‐positive Mac‐2 binding protein (WFA + ‐M2BP) for predicting hepatocellular carcinoma (HCC) in chronic hepatitis C patients who achieved sustained virologic response (SVR) by therapy with interferon‐free, direct‐acting antivirals (DAAs). Methods: This is a retrospective cohort study that included 567 patients who underwent antiviral therapy with an interferon‐free DAA regimen and achieved SVR. Serum WFA + ‐M2BP was measured after SVR. Factors predictive of HCC occurrence and recurrence were analyzed in the patients after stratification by previous treatment history of HCC. Results: Among 518 patients who had no history of HCC, 13 developed HCC. Post‐SVR WFA + ‐M2BP ≥1.75 cut‐off index (C.O.I., P < 0.001) and α‐fetoprotein (AFP) level ≥6 ng/mL ( P = 0.01) were significant predictors of HCC development. Multivariate analysis showed that post‐SVR WFA + ‐M2BP ≥1.75 C.O.I. was an independent factor significantly associated with the development of HCC (hazard ratio [HR] 6.0; 95% confidence interval (CI), 1.8–19.4; P = 0.003). Among 49 patients who had a previous history of HCC, 22 had recurrence after SVR. Post‐SVR AFP ≥6 ng/mL was the only factor associated with recurrence‐free survival (HR 3.1; 95% CI, 1.3–7.5; P = 0.01). Conclusions: Post‐SVR WFA + ‐M2BP is a predictive factor for the development of HCC in patients with no previous HCC history and treated with DAAs. Post‐SVR AFP was predictive for HCC recurrence after DAA therapy.